-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Reiterates Underperform on Eikon Therapeutics, Maintains $7 Price Target

Benzinga·03/31/2026 14:18:20
Listen to the news
Wedbush analyst Robert Driscoll reiterates Eikon Therapeutics (NASDAQ:EIKN) with a Underperform and maintains $7 price target.